Lack of evidence for an association of Epstein–Barr virus infection with breast carcinoma

Breast Cancer Research

Gerald Niedobitek¹  Kathrin Herrmann¹ 

[1] Institute for Pathology, Friedrich-Alexander University, Erlangen, Germany

关键词: in situ hybridisation;    immunohistology;    Epstein–Barr virus;    breast carcinoma;   

Others  :  1118815
DOI  :  10.1186/bcr561

 received in 2002-09-16, accepted in 2002-11-01,  发布年份 2002

【 摘 要 】

Background

Epstein–Barr virus (EBV) is a ubiquitous human γ-herpes virus infecting more than 90% of the population worldwide. EBV is associated with certain malignancies (e.g. Burkitt lymphoma, Hodgkin lymphoma and nasopharyngeal carcinoma). Recent studies have raised the possibility that EBV may also be involved in the pathogenesis of breast carcinoma, the most common carcinoma of females. If substantiated, this finding would have major implications regarding prevention and therapy of the disease. The studies published so far have employed diverse methods, however, and the results have been controversial.

Methods

Using the EBV DNA PCR, EBV DNA in situ hybridisation and in situ hybridisation for the detection of the EBV-encoded RNAs, and using immunohistochemistry for the demonstration of the EBV-encoded nuclear antigen 1, we have studied a series of 59 invasive breast carcinomas for evidence of EBV infection.

Results

EBV-encoded RNA-specific in situ hybridisation and EBV-encoded nuclear antigen 1 immunohistochemistry were negative in all cases. Using the PCR, EBV DNA was detected in four out of 59 cases. These cases were further studied by EBV DNA in situ hybridisation, showing an absence of viral DNA from the tumour cells.

Conclusion

These results indicate that breast carcinoma is not an EBV-associated tumour.

【 授权许可】

   
2003 Herrmann and Niedobitek, licensee BioMed Central Ltd

【 图 表 】

Figure 1.

【 参考文献 】

• [1]International Agency for Research on Cancer: Epstein–Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8. Lyon: World Health Organisation. 1997.
• [2]Labrecque LG, Barnes DM, Fentiman IS, Griffin BE: Epstein–Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res 1995, 55:39-45.
• [3]Bonnet M, Guinebretiere J-M, Kremmer E, Grunewald V, Benhamou E, Contesso G, Joab I: Detection of Epstein–Barr virus in invasive breast cancers. J Natl Cancer Inst 1999, 91:1376-1381.
• [4]Ambinder RF, Robertson KD, Moore SM, Yang J: Epstein–Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Semin Cancer Biol 1996, 7:217-226.
• [5]Sing AP, Ambinder RF, Hong DJ, Jensen M, Batten W, Petersdorf E, Greenberg PD: Isolation of Epstein–Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed–Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood 1997, 89:1978-1986.
• [6]Roskrow MA, Suzuki N, Gan Y-j, Sixbey JW, Ng CYC, Kimbrough S, Hudson M, Brenner MK, Heslop HE, Rooney CM: Epstein–Barr virus (EBV)-specific cytotoxic lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998, 91:2925-2934.
• [7]Niedobitek G, Hansmann ML, Herbst H, Young LS, Dienemann D, Hartmann CA, Finn T, Pitteroff S, Welt A, Anagnostopoulos I, Friedrich R, Lobeck H, Sam CK, Araujo I, Rickinson AB, Stein H: Epstein–Barr virus and carcinomas: undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus. J Pathol 1991, 165:17-24.
• [8]Lespagnard L, Cochaux P, Larsimont D, Degeyter M, Velu T, Heimann R: Absence of Epstein–Barr virus in medullary carcinoma of the breast as demonstrated by immunophenotyping, in situ hybridization and polymerase chain reaction. Am J Clin Pathol 1995, 103:449-452.
• [9]Dadmanesh F, Peterse JL, Sapino A, Fonelli A, Eusebi V: Lymphoepithelioma-like carcinoma of the breast: lack of evidence of Epstein–Barr virus infection. Histopathology 2001, 38:54-61.
• [10]Luqmani YA, Shousha S: Presence of Epstein–Barr virus in breast carcinoma. Int J Oncol 1995, 6:899-903.
• [11]Chu PG, Chang KL, Chen Y-Y, Weiss LM: No significant association of Epstein–Barr virus infection with invasive breast caricnoma. Am J Pathol 2001, 159:571-578.
• [12]Fina F, Romain S, Ouafik L, Palmari J, Ben Ayed F, Benharkat S, Bonnier P, Spyratos F, Foekens JA, Rose C, Buisson M, Gerard H, Reymond MO, Seigneurin JM, Martin PM: Frequency and genome load of Epstein–Barr virus in 509 breast cancers from different geographic areas. Br J Cancer 2001, 84:783-790.
• [13]McCall SA, Lichy JH, Bijwaard KE, Aguilera NS, Chu W-S, Taubenberger JK: Epstein–Barr virus detection in ductal carcinoma of the breast. J Natl Cancer Inst 2001, 93:148-150.
• [14]Glaser SL, Ambinder RF, DiGuiseppe JA, Horn-Ross PL, Hsu JL: Absence of Epstein–Barr virus EBER-1 transcripts in an epidemiologically diverse group of breast cancers. Int J Cancer 1998, 75:555-558.
• [15]Chu JS, Chen CC, Chang KJ: In situ detection of Epstein–Barr virus in breast cancer. Cancer Lett 1998, 124:53-57.
• [16]Grinstein S, Preciado MV, Gattuso P, Chabay PA, Warren WH, De Matteo E, Gould VE: Demonstration of Epstein–Barr virus in carcinomas of various sites. Cancer Res 2002, 62:4876-4878.
• [17]Raab-Traub N, Flynn K: The structure of the termini of the Epstein–Barr virus as a marker of clonal cellular proliferation. Cell 1986, 47:883-889.
• [18]Grässer FA, Murray PG, Kremmer E, Klein K, Remberger K, Feiden W, Reynolds G, Niedobitek G, Young LS, Mueller-Lantzsch N: Monoclonal antibodies directed against the Epstein–Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 1994, 84:3792-3798.
• [19]Murray PG, Niedobitek G, Kremmer E, Grasser F, Reynolds GM, Cruchley A, Williams DM, Muller-Lantzsch N, Young LS: In situ detection of the Epstein–Barr virus-encoded nuclear antigen 1 in oral hairy leukoplakia and virus-associated carcinomas. J Pathol 1996, 178:44-47.
• [20]Sugawara Y, Mizugaki Y, Uchida T, Torii T, Imai S, Makuuchi M, Takada K: Detection of Epstein–Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression. Virology 1999, 256:196-202.
• [21]Niedobitek G, Young LS, Lau R, Brooks L, Greenspan D, Greenspan JS, Rickinson AB: Epstein–Barr virus infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase. J Gen Virol 1991, 72:3035-3046.
• [22]Niedobitek G, Herbst H: In situ detection of Epstein–Barr virus DNA and of viral gene products. In In Epstein–Barr Virus Protocols. Edited by Wilson JB, May GHW. Totowa, NJ: Humana Press; 2001:79-91.
• [23]Yates J, Waren N, Reisman D, Sugden B: A cis-acting element from the Epstein–Barr virus genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 1984, 81:3806-3810.
• [24]Nicholls JM, Agathanggelou A, Fung K, Xianggou Z, Niedobitek G: The association of squamous cell carcinomas of the nasopharynx with Epstein–Barr virus shows geographic variation reminiscent of Burkitt's lymphoma. J Pathol 1997, 183:164-168.